Brief: Cantargia Reports Encouraging New CAN10 Toxicology Results

Cantargia AB

22/02/2022 14:14

Feb 22 (Reuters) - Cantargia AB  CANTA.ST :
    * CANTARGIA REPORTS ENCOURAGING NEW CAN10 TOXICOLOGY RESULTS
AND
SCHEDULES PHASE I TRIAL FOR 2023
    * RESULTS SHOW NO TOXICOLOGICALLY RELEVANT CHANGES USING A
NEW
SUBCUTANEOUS FORMULATION, WITH HIGH BIOAVAILABILITY AND
DESIRABLE PHARMACOLOGICAL HALF-LIFE
    * GLP TOXICOLOGY STUDIES FOR CAN10 ARE SCHEDULED TO START Q2
2022,
WITH TIMELINES SLIGHTLY ADJUSTED TO FIT WITH GLOBAL CAPACITY
DURING COVID PANDEMIC.
    * PHASE I CLINICAL TRIAL FOR CAN10 IS NOW EXPECTED TO START
EARLY
2023

Source text for Eikon:  ID:nWkr9F9mJ1 
Further company coverage:  CANTA.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))